A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Ivacaftor (Primary) ; Lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Registrational
- Sponsors Vertex Pharmaceuticals
- 09 Aug 2017 Planned number of patients changed from 245 to 240.
- 09 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated